Decitabine/Venetoclax Conditioning As Alternative Lymphodepletion Strategy for Adoptive Cell Therapy

Key Points

• Decitabine and venetoclax effectively enhance lymphodepletion during adoptive cell therapy, increasing treatment potential.
• Key evidence shows significant lymphodepletion efficacy enabling a better immune response.
• Analysis of treatment outcomes indicates the feasibility of using decitabine and venetoclax as conditioning agents.
• Implications suggest that combining these agents may improve the overall success of adoptive cell therapies, warranting further investigation.